Ostrava

• Phase 3 study of adjuvant V940 and Pembrolizumab in resected Stage II, IIIA, IIIB NSCLC Recruiting
  2023-504923-20-00 5 2024-04-04 Stage II, IIIA, IIIB (N2) Non-small Cell Lung Cancer
• A Global Pivotal Placebo-Controlled Study of LY3537982 in Combination with Pembrolizumab and LY3537982 in Combination with Pembrolizumab, Pe … Recruiting
  2023-503412-33-00 5 2024-03-29 Stage IIIB-IIIC or Stage IV KRAS G12C-mutant non-small cell lung cance
• A clinical study to compare MK-2870 with pembrolizumab to pembrolizumab alone in people with lung cancer (MK-2870-007) Recruiting
  2023-503376-24-00 5 2024-03-20 Metastatic non-small cell lung cancer (NSCLC)
• An international randomised trial of radical surgery followed by adjuvant therapy versus no further treatment in patients with early-stage, … Recruiting
  2023-504973-19-01 5 2023-09-06 early-stage, intermediate-risk cervical cancer
• A study of fibrinogen concentrate (FGTW) compared to placebo in the management of bleeding in patients undergoing complex cardiac surgery Recruiting
  2024-512388-29-00 5 2022-11-29 Bleeding in patients undergoing complex cardiac surgery involving Card
• A Phase 3 Randomized Study Comparing Teclistamab in Combination with Daratumumab SC and Lenalidomide (Tec-DR) and Talquetamab in Combination … Recruiting
  2023-503442-30-00 5 2022-10-14 Multiple Myeloma
• Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone versus Lenalidomide Alone in Participants With Newly Dia … Recruiting
  2023-510384-36-00 5 2022-09-13 Newly Diagnosed Multiple Myeloma
• A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SLL Recruiting
  2023-507699-38-00 5 2022-08-30 Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
• A Phase 1b Open-Label Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination with Other Anti-cancer … Recruiting
  2024-512089-32-00 3 2022-03-28 Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction Recruiting
  2023-505438-85-00 5 2022-01-12 Acute myocardial infarction (AMI)
• Randomised Placebo-Controlled Trial of Early Targeted Treatment of Patent Ductus Arteriosus with Paracetamol in Extremely Low Birth Weight I … Recruiting
  2024-516846-20-00 5 2021-09-26 Patent Ductus Arteriosus
• Roll Over Study for Patients Who Have Completed a Previous Oncology Study with Olaparib Recruiting
  2024-512982-15-00 5 2021-06-28 BRCA Mutated Ovarian Cancer Patients, Epithelian ovarian cancer, Metas
• A study investigating single injection of new botulinum toxin to determine safety and efficacy for treating spasticity in the upper limb Recruiting
  2023-507202-14-00 7 2021-04-29 Upper limb spasticity after stroke or traumatic brain injury
• Phase 2 Study of Adagrasib Monotherapy and in Combination With Pembrolizumab and Phase 3 Study of Adagrasib in Combination with Pembrolizuma … Recruiting
  2023-508922-83-00 10 2021-03-17 Advanced Non-Small Cell Lung Cancer
• Randomized phase III trial on NIraparib-Dostarlimab vs physician’s choice CHEmotherapy in recurrent, ovarian, fallopian tube or primary peri … Recruiting
  2024-516649-38-00 5 2020-12-01 Recurrent ovarian, fallopian tube or primary peritoneal cancer
• Goal directed fluid removal in critically ill patients with fluid overload Recruiting
  2024-512186-14-00 6 2020-08-24 Fluid overload/fluid accumulation
• Long-Term Follow-up Protocol for Subjects Treated with Gene-Modified T cells. Recruiting
  2023-504201-36-00 10 2018-12-21 Defined by parent protocol. The study will enroll all adult and paedia
• Assessing the Impact of Muvalaplin on Major Cardiovascular Events in Adults With Elevated Lipoprotein(a) ( MOVE-Lp(a) ) Ended recruitment
  2025-521067-13-00 5 2026-04-24 Atherosclerotic Cardiovascular Disease (ASCVD)
• MK-2870 versus Chemotherapy in Previously Treated or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) with EGFR Mutations or Other … Ended recruitment
  2023-503539-16-00 5 2025-11-11 Non-small Cell Lung Cancer (NSCLC)
• A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous Ublituximab in Partici … Ended recruitment
  2025-521127-73-00 5 2025-09-12 Relapsing forms of Multiple Sclerosis
• J2A-MC-GZPO: A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes J2 … Ended recruitment
  2025-521098-14-00 5 2025-08-15 GZP1, GZP2: Obesity, Overweight GZP2: Type 2 Diabetes
• A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Evaluating the Efficacy of Transfer Factor TFI Treatment by Assessing the Numb … Ended recruitment
  2024-516879-32-00 5 2025-06-13 • Recurrent respiratory infections • Recurrent urinary tract infectio
• LUCIA: A Phase 3 randomized, double-masked study comparing the efficacy of EYP-1901 against aflibercept Ended recruitment
  2024-518030-83-00 5 2025-06-05 Wet age-related macular degeneration (wAMD)
• A Phase 2 Open-Label Safety and Efficacy Study of PF-06835375 Ended recruitment
  2023-509338-21-00 4 2025-05-28 Primary immune thrombocytopenia

Showing 121–144 of 253 trials